To provide further experimental evidence for the generation of anti-BP180 IgG in patients with neurological diseases, Kokkonen and co-workers tested 115 Alzheimer’s disease patients and 40 neurologically healthy controls for anti-BP180 IgG. Here, COL17A1 is linked to nervous system disorder.